ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Biosight Receives Orphan Drug Designation for BST-236 for AML americanpharmaceuticalreview
June 06, 2019Biosight announced the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to?BST-236, an investigational novel antimetabolite, for the treatment of acute myeloid leukemia (AML).
Pharma Sources Insight January 2025
